TacticScaleWhat Bruker Does & How It Makes Money (BRKR)
Updated October 2026 · reflects Bruker's latest reported financials
Maker of high-end scientific instruments and diagnostic tools for labs. Bruker earns most of its money selling high-value analytical instruments across four segments, plus recurring revenue from consumables and test kits, services, lifecycle support, aftermarket solutions and software.
How Bruker makes money
Bruker earns most of its money selling high-value analytical instruments across four segments, plus recurring revenue from consumables and test kits, services, lifecycle support, aftermarket solutions and software. A separate segment sells superconducting wire and related high-tech components.
What Bruker does
Bruker Corporation, founded in 1960 and headquartered in Billerica, Massachusetts, develops and sells scientific instruments and analytical and diagnostic solutions. It reports through four segments. BSI BioSpin covers magnetic resonance (NMR and EPR) and preclinical imaging. BSI CALID covers mass spectrometry, molecular diagnostics and detection systems. BSI Nano covers X-ray, atomic force microscopy, optical microscopy and semiconductor metrology tools. Bruker Energy & Supercon Technologies makes superconducting materials and wire. Its customers range from academic and pharmaceutical research labs to clinical microbiology, applied and industrial users, and semiconductor makers. Besides instrument sales, Bruker earns revenue from services, lifecycle support, aftermarket products, lab automation and data software, and diagnostic consumables. Much of its business is tied to research and biopharma spending.
Products & services
- NMR and EPR magnetic resonance spectrometers
- Mass spectrometry systems and microbial identification solutions
- X-ray fluorescence (XRF) and X-ray metrology instruments
- Atomic force microscopes (AFM) and fluorescence microscopy
- Molecular diagnostic kits (DNA test strips, PCR assays)
- Low-temperature superconducting (LTS) wire
What is Bruker worth?
On an owner-earnings DCF, Bruker's most-likely value is about $36 versus a recent price near $59 (38% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$18) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
⚠ High leverage — net debt is 7.4× annual cash flow. Net debt is subtracted from this fair value, but refinancing at higher rates, principal timing, and share dilution aren’t modeled — the equity can be worth far less if cash flow weakens.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Bio-Rad Laboratories (BIO) · Boston Scientific (BSX) · Waters (WAT) · Danaher (DHR) · Thermo Fisher Scientific (TMO)